Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT04244656 |
Title | A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma |
Recruitment | Active, not recruiting |
Gender | both |
Phase | Phase I |
Variant Requirements | No |
Sponsors | CRISPR Therapeutics AG |
Indications | |
Therapies | |
Age Groups: | adult | senior |
Covered Countries | USA | ESP | CAN | AUS |
Facility | Status | City | State | Zip | Country | Details |
---|---|---|---|---|---|---|
University of Chicago | Chicago | Illinois | 60637 | United States | Details | |
Oregon Health and Science University | Portland | Oregon | 97239 | United States | Details | |
University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | United States | Details | |
Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | United States | Details | |
Royal Prince Alfred Hospital | Sydney | New South Wales | 2050 | Australia | Details | |
Peter MacCallum Cancer Centre | Melbourne | Victoria | 3000 | Australia | Details | |
University Health Network, Princess Margaret Cancer Centre | Toronto | Ontario | M5G 1X6 | Canada | Details | |
Institut Catala d'Oncologia Hospital Germans Trias i Pujol | Badalona | Barcelona | 08916 | Spain | Details | |
Universidad de Navarra | Pamplona | Navarra | 31008 | Spain | Details | |
Hospital Universitario de Salamanca | Salamanca | 37007 | Spain | Details |